Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC).
BT-549
FAK
Hippo/YAP
MDA-MB-231
RAGE
S100A8/A9
TNBC
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
03 Jun 2022
03 Jun 2022
Historique:
received:
23
03
2022
accepted:
17
05
2022
entrez:
2
6
2022
pubmed:
3
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Understanding the intricate signaling network involved in triple-negative breast cancer (TNBC) represents a challenge for developing novel therapeutic approaches. Here, we aim to provide novel mechanistic insights on the function of the S100A8/A9-RAGE system in TNBC. TNM plot analyzer, Kaplan-Meier plotter, Meta-analysis, GEPIA2 and GOBO publicly available datasets were used to evaluate the clinical significance of S100A8/A9 and expression levels of S100A8/A9, RAGE and Filamin family members in breast cancer (BC) subtypes. METABRIC database and Cox proportional hazard model defined the clinical impact of high RAGE expression in BC patients. Multiple bioinformatics programs identified the main enriched pathways within high RAGE expression BC cohorts. By lentiviral system, TNBC cells were engineered to overexpress RAGE. Western blotting, immunofluorescence, nucleus/cytoplasm fractionation, qRT-PCR, gene silencing and luciferase experiments were performed to identify signal transduction mediators engaged by RAGE upon stimulation with S100A8/A9 in TNBC cells. Proliferation, colony formation and transwell migration assays were carried out to evaluate the growth and migratory capacity of TNBC cells. Statistical analysis was performed by ANOVA and independent t-tests. We found a remarkable high expression of S100A8 and S100A9 in BC, particularly in HER2-positive and TNBC, with the latter associated to worst clinical outcomes. In addition, high RAGE expression correlated with a poor overall survival in BC. Next, we determined that the S100A8/A9-RAGE system triggers FAK activation by engaging a cytoskeleton mechanosensing complex in TNBC cells. Through bioinformatics analysis, we identified the Hippo pathway as the most enriched in BC patients expressing high RAGE levels. In accordance with these data, we demonstrated the involvement of S100A8/A9-RAGE-FAK signaling in the control of Hippo/YAP activities, and we established the crucial contribution of RAGE-FAK-YAP circuitry in the growth and migratory effects initiated by S100A8/A9 in TNBC cells. The present study provides novel mechanistic insights on RAGE actions in TNBC. Moreover, our findings suggest that RAGE-FAK-YAP transduction pathway could be exploited as a druggable system halting the aggressive TNBC subtype.
Sections du résumé
BACKGROUND
BACKGROUND
Understanding the intricate signaling network involved in triple-negative breast cancer (TNBC) represents a challenge for developing novel therapeutic approaches. Here, we aim to provide novel mechanistic insights on the function of the S100A8/A9-RAGE system in TNBC.
METHODS
METHODS
TNM plot analyzer, Kaplan-Meier plotter, Meta-analysis, GEPIA2 and GOBO publicly available datasets were used to evaluate the clinical significance of S100A8/A9 and expression levels of S100A8/A9, RAGE and Filamin family members in breast cancer (BC) subtypes. METABRIC database and Cox proportional hazard model defined the clinical impact of high RAGE expression in BC patients. Multiple bioinformatics programs identified the main enriched pathways within high RAGE expression BC cohorts. By lentiviral system, TNBC cells were engineered to overexpress RAGE. Western blotting, immunofluorescence, nucleus/cytoplasm fractionation, qRT-PCR, gene silencing and luciferase experiments were performed to identify signal transduction mediators engaged by RAGE upon stimulation with S100A8/A9 in TNBC cells. Proliferation, colony formation and transwell migration assays were carried out to evaluate the growth and migratory capacity of TNBC cells. Statistical analysis was performed by ANOVA and independent t-tests.
RESULTS
RESULTS
We found a remarkable high expression of S100A8 and S100A9 in BC, particularly in HER2-positive and TNBC, with the latter associated to worst clinical outcomes. In addition, high RAGE expression correlated with a poor overall survival in BC. Next, we determined that the S100A8/A9-RAGE system triggers FAK activation by engaging a cytoskeleton mechanosensing complex in TNBC cells. Through bioinformatics analysis, we identified the Hippo pathway as the most enriched in BC patients expressing high RAGE levels. In accordance with these data, we demonstrated the involvement of S100A8/A9-RAGE-FAK signaling in the control of Hippo/YAP activities, and we established the crucial contribution of RAGE-FAK-YAP circuitry in the growth and migratory effects initiated by S100A8/A9 in TNBC cells.
CONCLUSIONS
CONCLUSIONS
The present study provides novel mechanistic insights on RAGE actions in TNBC. Moreover, our findings suggest that RAGE-FAK-YAP transduction pathway could be exploited as a druggable system halting the aggressive TNBC subtype.
Identifiants
pubmed: 35655319
doi: 10.1186/s13046-022-02396-0
pii: 10.1186/s13046-022-02396-0
pmc: PMC9164429
doi:
Substances chimiques
Focal Adhesion Protein-Tyrosine Kinases
EC 2.7.10.2
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
193Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 21651
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 23369
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 21322
Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2015 Mar 26;10(3):e0120971
pubmed: 25811984
Sci Adv. 2021 Jan 1;7(1):
pubmed: 33523865
Horm Cancer. 2018 Oct;9(5):295-325
pubmed: 29987748
Nat Commun. 2015 Dec 16;6:10186
pubmed: 26671411
Sci Transl Med. 2020 Dec 2;12(572):
pubmed: 33268511
Neoplasia. 2019 Jul;21(7):627-640
pubmed: 31100639
Carcinogenesis. 2008 Oct;29(10):2035-43
pubmed: 18689872
Nat Commun. 2016 Jan 04;7:10259
pubmed: 26725330
Clin Transl Med. 2021 Jul;11(7):e459
pubmed: 34323409
PLoS One. 2011 Mar 21;6(3):e17911
pubmed: 21445301
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Nat Rev Cancer. 2015 Feb;15(2):96-109
pubmed: 25614008
Oncogene. 2017 Mar;36(11):1559-1572
pubmed: 27669433
Patterns (N Y). 2021 Mar 04;2(3):100213
pubmed: 33748796
Oncoscience. 2016 Mar 03;3(2):52-3
pubmed: 27014721
J Cell Physiol. 2021 Oct;236(10):7014-7032
pubmed: 33748944
J Hepatol. 2021 Oct;75(4):888-899
pubmed: 34052254
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113
pubmed: 34754128
Oncol Lett. 2012 May;3(5):1149-1153
pubmed: 22783409
Neoplasma. 2021 Jan;68(1):71-78
pubmed: 33030958
Nat Cell Biol. 2021 Nov;23(11):1187-1198
pubmed: 34737445
Breast Cancer Res Treat. 2014 Nov;148(1):41-59
pubmed: 25270120
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Int J Lab Hematol. 2021 Aug;43(4):638-644
pubmed: 33904653
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Breast Cancer Res Treat. 2013 Nov;142(2):297-309
pubmed: 24177755
Mol Cancer Res. 2008 Oct;6(10):1544-53
pubmed: 18922970
J Exp Clin Cancer Res. 2022 Feb 8;41(1):54
pubmed: 35135586
Expert Opin Investig Drugs. 2015 Mar;24(3):393-9
pubmed: 25586103
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Mol Cancer Ther. 2018 Dec;17(12):2689-2701
pubmed: 30237308
Nature. 2000 May 18;405(6784):354-60
pubmed: 10830965
Inflamm Res. 2018 Oct;67(10):801-812
pubmed: 30083975
Acta Biomater. 2022 Mar 15;141:255-263
pubmed: 35081431
N Engl J Med. 2022 Feb 10;386(6):556-567
pubmed: 35139274
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Front Oncol. 2018 Nov 05;8:496
pubmed: 30456203
Structure. 2010 Oct 13;18(10):1342-52
pubmed: 20947022
Cell Immunol. 2021 Jul;365:104379
pubmed: 34038758
Cancer Res. 2015 Mar 15;75(6):974-85
pubmed: 25572331
Nat Commun. 2017 Jan 19;8:14073
pubmed: 28102225
J Exp Clin Cancer Res. 2016 Apr 02;35:62
pubmed: 27039292
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807717
J Immunother Cancer. 2019 Dec 5;7(1):343
pubmed: 31806053
Structure. 2016 Dec 6;24(12):2043-2052
pubmed: 27818100
Nat Rev Mol Cell Biol. 2001 Feb;2(2):138-45
pubmed: 11252955
Ann Oncol. 2020 May;31(5):569-581
pubmed: 32278621
Lancet. 2020 Oct 10;396(10257):1090-1100
pubmed: 32966830
Nat Rev Cancer. 2015 Feb;15(2):73-79
pubmed: 25592648
Br J Cancer. 2015 Oct 20;113(8):1234-43
pubmed: 26448179
Oncotarget. 2018 Jun 26;9(49):29064-29081
pubmed: 30018736
Curr Opin Cell Biol. 2017 Apr;45:24-30
pubmed: 28213315
Nucleic Acids Res. 2012 Jan;40(Database issue):D1144-9
pubmed: 22086960
Oncotarget. 2016 May 31;7(22):31602-22
pubmed: 27203208
Curr Protoc. 2021 Mar;1(3):e90
pubmed: 33780170
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Mol Cancer Res. 2011 Feb;9(2):133-48
pubmed: 21228116
Mol Cell Proteomics. 2008 Aug;7(8):1420-33
pubmed: 18426791
J Exp Clin Cancer Res. 2021 Jan 9;40(1):27
pubmed: 33422090
Cells. 2020 Apr 18;9(4):
pubmed: 32325700
Oncol Lett. 2016 Mar;11(3):1936-1942
pubmed: 26998104
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
BMC Cancer. 2014 Dec 17;14:970
pubmed: 25518851
J Cell Physiol. 2012 Jun;227(6):2722-9
pubmed: 21898412
Biochim Biophys Acta. 2015 Mar;1852(3):429-41
pubmed: 25514746
Pharmacol Ther. 2016 Nov;167:120-131
pubmed: 27492899
Oncol Res Treat. 2016;39(10):622-628
pubmed: 27710974
Int J Biol Sci. 2013;9(1):67-77
pubmed: 23289018
Int J Mol Sci. 2020 May 20;21(10):
pubmed: 32443845
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Cell Mol Med. 2016 May;20(5):825-35
pubmed: 26928771
Clin Cancer Res. 2012 Aug 15;18(16):4356-64
pubmed: 22718861
Anticancer Drugs. 2019 Mar;30(3):225-232
pubmed: 30334817
Blood. 2019 Oct 17;134(16):1279-1288
pubmed: 31471375
J Exp Clin Cancer Res. 2019 Feb 6;38(1):58
pubmed: 30728047
Nature. 2012 Apr 04;486(7403):395-9
pubmed: 22495314
Nat Cell Biol. 2021 Jul;23(7):758-770
pubmed: 34226698
Mol Med Rep. 2018 Sep;18(3):2621-2630
pubmed: 30015912
Biomaterials. 2021 Dec;279:121185
pubmed: 34808560
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Expert Opin Drug Discov. 2022 Apr;17(4):365-376
pubmed: 35179448
Oncogene. 2020 Jul;39(27):5015-5030
pubmed: 32523092
Nat Med. 2022 Apr;28(4):752-765
pubmed: 35411077
Curr Cancer Drug Targets. 2008 Jun;8(4):243-52
pubmed: 18537548
J Exp Clin Cancer Res. 2018 Jul 28;37(1):175
pubmed: 30055645
Cancers (Basel). 2020 Jul 24;12(8):
pubmed: 32722137
J Exp Clin Cancer Res. 2019 Jun 11;38(1):250
pubmed: 31186061
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Gene. 2021 Jun 5;784:145575
pubmed: 33737122
Comput Struct Biotechnol J. 2021 Jul 18;19:4101-4109
pubmed: 34527184
Cancer Cell. 2019 Jan 14;35(1):64-80.e7
pubmed: 30612941
Cancer Res. 2008 Oct 15;68(20):8210-20
pubmed: 18922892
Cell Death Dis. 2020 Apr 23;11(4):265
pubmed: 32327633
Biochem Biophys Res Commun. 2013 May 3;434(2):328-33
pubmed: 23537648
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Tumour Biol. 2016 Apr;37(4):5107-15
pubmed: 26546439